Preliminary Programme

25 - 27 March 2020
Bruges • Belgium
www.lupus2020.eu
Join us in Bruges!

Together with the International Scientific Committee members, we take great pleasure in inviting you to the 12th European Lupus Meeting, taking place in Bruges, Belgium on 25 - 27 March 2020.

The meeting is intended to share the latest clinical and basic advances in the field of systemic lupus erythematosus with two concurrent sessions combining invited talks and oral abstract presentations.

We have also scheduled a Great Debate, Meet the Professor and Fishbowls sessions, the latter to increase interactions between participants. The best experts have been invited. We are therefore convinced that many basic and clinical researchers will be happy to discuss their new data and to enjoy lovely Bruges.

For indeed, Bruges - deservedly nicknamed ‘Venice of the North’ - has a lot on offer: a magnificent historic centre, internationally acclaimed museums and remarkable monuments, a green recreation belt and myriads of restaurants and colourful pavement cafés. You will find Bruges to be an exquisite small city bustling with activities.

The 12th European Lupus Meeting will be the perfect occasion to meet up with old friends and to make new ones. Join us in Bruges and have a great time!

Frédéric Houssiau & Nathalie Costedoat-Chalumeau
Congress Chairs
Organising Secretariat
Medicongress Services NV
Noorwegenstraat 49
9940 Evergem
Belgium
Phone: +32 (0) 9 218 85 85
lupus2020@medicongress.com
www.lupus2020.eu

Board of the European Lupus Society
President 2019  Frédéric Houssiau, Brussels (BE)
President Elect  Elisabet Svenungsson, Stockholm (SE)
Past President  Matthias Schneider, Düsseldorf (DE)
General Secretary  Luis Pedro Sousa Inês, Coimbra (PT)
Treasurer  Andrea Doria, Padova (IT)
Members  Dimitrios Boumpas, Athens (GR)
Ricard Cervera, Barcelona (ES)
Carlo Chizzolini, Geneva (CH)
Nathalie Costedoat-Chalumeau, Paris (FR)
Anisur Rahman, London (UK)
Maria Tektonidou, Athens (GR)
Ronald van Vollenhoven, Amsterdam (NL)

SLEuro – the European Lupus Society – is a voluntary and non-political association for scientists and medical doctors in the field of SLE and related syndromes and was founded in Venice, Italy in 2016. SLEuro welcomes new applications for membership from both individuals and institutions of any nationality who share its purposes. As a member, you’ll enjoy access to a network of peers and mentors from across Europe and the globe, reduced rates for attending the biennial European Lupus Meeting and a variety of educational contents.

To become a member, go to: http://www.sleuro.org/membership for further information.

11.30 - 12.30  Pre-meeting Course (tbc)
13.00 - 14.00  Satellite Symposium

Session 1: Optimizing the use of old drugs
Concert Hall
14.00  Why should all patients take hydroxychloroquine? (I1)
Guillermo Ruiz-Irastorza, Biskaia, Spain
14.20  Optimal use of glucocorticoids (I2)
Luís Sousa Inês, Coimbra, Portugal
14.40  My ten top tips to improve adherence
Nathalie Costedoat-Chalumeau, Paris, France
15.00  Selected Oral Presentations
O1 Hydroxychloroquine blood levels and risk of thrombotic events in Systemic Lupus Erythematosus
Michelle Petri, Baltimore, USA
O2 Effect of treatment on antiphospholipid antibodies in SLE
Michelle Petri, Baltimore, USA
O3 Changes in gut microbiota after synbiotic supplementation in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Alvina Widhani, Jakarta, Indonesia
15.30  Coffee Break
### Programme • Wednesday 25 March

#### Session 3: Pregnancy

**Concert Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Practical management of pregnancy</td>
</tr>
<tr>
<td></td>
<td>Rebecca Fischer-Betz, Düsseldorf, Germany</td>
</tr>
<tr>
<td>16.20</td>
<td>Planning and management of pregnancy in lupus nephritis (I4)</td>
</tr>
<tr>
<td></td>
<td>David D’Cruz, London, UK</td>
</tr>
<tr>
<td>16.40</td>
<td>Practical management of APS pregnancy</td>
</tr>
<tr>
<td></td>
<td>Munther Khamashta, Dubai, UAE</td>
</tr>
<tr>
<td>17.00</td>
<td>Long-term outcome of children born to lupus patients</td>
</tr>
<tr>
<td></td>
<td>Angela Tincani, Brescia, Italy</td>
</tr>
<tr>
<td>17.20</td>
<td>Selected Oral Presentation</td>
</tr>
<tr>
<td>07</td>
<td>Safety of chloroquine and hydroxychloroquine during pregnancy: A systematic literature review and meta-analysis</td>
</tr>
<tr>
<td></td>
<td>Christoph Richez, Bordeaux, France</td>
</tr>
<tr>
<td>17.30</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

#### Session 4: Classification and subtypes

**Chamber Music Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Defining lupus: Chances and challenges based on the EULAR/ACR criteria (I5)</td>
</tr>
<tr>
<td></td>
<td>Martin Aringer, Dresden, Germany</td>
</tr>
<tr>
<td>16.20</td>
<td>Dwelling into SLE heterogeneity</td>
</tr>
<tr>
<td></td>
<td>Carlo Chizzolini, Geneva, Switzerland</td>
</tr>
<tr>
<td>16.40</td>
<td>Clinical subtypes of SLE: Can we push forward?</td>
</tr>
<tr>
<td></td>
<td>Carlos Vasconcelos, Porto, Portugal</td>
</tr>
<tr>
<td>17.00</td>
<td>Molecular reclassification of autoimmune rheumatic diseases</td>
</tr>
<tr>
<td></td>
<td>John Ioannou, London, UK</td>
</tr>
<tr>
<td>17.20</td>
<td>Selected Oral Presentation</td>
</tr>
<tr>
<td>08</td>
<td>Performance of the EULAR/ACR 2019 classification criteria for Systemic Lupus Erythematosus in men, ethnicities, and early disease</td>
</tr>
<tr>
<td></td>
<td>Martin Aringer, Dresden, Germany</td>
</tr>
</tbody>
</table>

#### Opening Ceremony

**Concert Hall**

- 18.00 Official Opening of the Lupus 2020 Meeting
  - Frédéric Houssiau and Nathalie Costedoat-Chalumeau, Congress Chairs

### Programme • Thursday 26 March

#### Session 5: Targeted therapy

**Concert Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Key to success in clinical trials</td>
</tr>
<tr>
<td></td>
<td>Ronald Van Vollenhoven, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>09.20</td>
<td>Update on new biological treatments</td>
</tr>
<tr>
<td></td>
<td>Alexandre Voskuil, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>09.40</td>
<td>How close are we to personalized medicine?</td>
</tr>
<tr>
<td></td>
<td>Ian Bruce, Manchester, UK</td>
</tr>
<tr>
<td>10.00</td>
<td>Selected Oral Presentations</td>
</tr>
<tr>
<td>09</td>
<td>Reduction of interferon-γ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE</td>
</tr>
<tr>
<td></td>
<td>Frédéric Baribaud, Springhouse, USA</td>
</tr>
<tr>
<td>10</td>
<td>Prediction of response to rituximab in SLE using a validated two-score system for interferon status</td>
</tr>
<tr>
<td></td>
<td>Edward Vital, Manchester, UK</td>
</tr>
<tr>
<td>10.10</td>
<td>AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in Lupus Nephritis (LN)</td>
</tr>
<tr>
<td></td>
<td>Onno Teng, Leiden, The Netherlands</td>
</tr>
</tbody>
</table>

#### Session 6: What really matters for patients?

**Chamber Music Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Patient’s expectations (I7)</td>
</tr>
<tr>
<td></td>
<td>Alain Cornet, Brussels, Belgium</td>
</tr>
<tr>
<td>09.20</td>
<td>How to reconcile physician’s and patient’s treatment targets</td>
</tr>
<tr>
<td></td>
<td>Marta Mosca, Pisa, Italy</td>
</tr>
<tr>
<td>09.40</td>
<td>Cutaneous lupus erythematosus in daily practice</td>
</tr>
<tr>
<td></td>
<td>Dan Lipsker, Strasbourg, France</td>
</tr>
<tr>
<td>10.00</td>
<td>Selected Oral Presentations</td>
</tr>
<tr>
<td>09</td>
<td>Erosive arthritis in Systemic Lupus Erythematosus: A cluster analysis</td>
</tr>
<tr>
<td></td>
<td>Fulvia Ceccarelli, Roma, Italy</td>
</tr>
<tr>
<td>09</td>
<td>Remission and LLDAS as a target for pregnancy planning in SLE?</td>
</tr>
<tr>
<td></td>
<td>Dina Zucchi, Pisa, Italy</td>
</tr>
<tr>
<td>09</td>
<td>The influence of antiphospholipid-antibodies on INR values measured with the CoaguChek</td>
</tr>
<tr>
<td></td>
<td>Chong Ying Wong, Utrecht, The Netherlands</td>
</tr>
</tbody>
</table>
10.30 Coffee break

Session 7: Outcome measures

Concert Hall

11.00 Derivation and validation of the Lupus Low Disease Activity State
Eric Morand, Melbourne, Australia

11.20 Lupus remission in clinical practice and in RCT
Andrea Doria, Padua, Italy

11.40 Optimal trial design
Matthias Schneider, Düsseldorf, Germany

12.00 Selected Oral Presentations

O15 Concordance between the new SLE-DAS, DORIS and Doria remission criteria for SLE: Are they different in a real-life clinical setting?
Heléna Assunção, Coimbra, Portugal

O16 Do we need physician global assessment for remission in SLE? Analysis from an SLE-cohort at a tertiary center
Johanna Mucke, Düsseldorf, Germany

O17 Treatment target in newly diagnosed SLE patients: Low disease activity and remission are independently associated with lower accrual of early damage
Matteo Piga, Cagliari, Italy

O18 Testing the performance of the different items included in the definition of remission in a multicenter cohort of patients with Systemic Lupus Erythematosus
Francesca Saccom, Padova, Italy

Session 8: Pathophysiology of lupus nephritis

Chamber Music Hall

11.00 Tubulointerstitial inflammation
Marcus Clark, Chicago, USA

11.20 Systemic versus local innate immunity
Hans-Joachim Anders, München, Germany

11.40 Intra-renal activation of adaptive immune effectors
Bernard Lauwerys, Brussels, Belgium

12.00 Selected Oral Presentations

O19 Evolution of kidney antibody secreting cells molecular signature in lupus patients with active nephritis upon immunosuppressive therapy
Etienne Crickx, Paris, France

O20 Marginal zone B cell development from early T2 progenitors is defective in lupus nephritis
Thomas Tull, London, UK

O21 Analysis of B-cell infiltrates and tertiary lymphoid organ in Lupus Nephritis
Fahd Touzani, Brussels, Belgium

O22 Correlation between interstitial CDB+ T cell infiltration and fibrotic processes in a mouse model of lupus nephritis
Pauline Montigny, Louvain, Belgium

12.40 Lunch break and Poster Viewing
13.00 Poster Presenters of P1 – P100 are invited to be at their posters for Q&A
13.30 SLEuro Executive Board Meeting
13.30 Satellite Symposium

Session 9: Role of interferons

Concert Hall

14.30 The role of the interferon system in SLE (I8)
Lars Rönnblom, Uppsala, Sweden

14.50 Interferon activity to monitor lupus activity
Zahir Amoura, Paris, France

15.00 Clinical trials with IFN blockers (I9)
Richard Furie, New York, USA

15.30 Selected Oral Presentations

O23 Identification of protein-Quantitative Trait Loci (pQTLs) in the interferon signalling pathway
Christian Lundtoft, Uppsala, Sweden

O24 Flare assessments in patients with active Systemic Lupus Erythematosus treated with anifrolumab in 2 phase 3 trials
Richard Furie, Great Neck, USA

Eric Morand, Melbourne, Australia

Session 10: Comorbidities

Chamber Music Hall

14.30 Life-threatening outcomes with special emphasis on infection
Maria Tektonidou, Athens, Greece

14.50 Cardiovascular disease burden and biomarkers in SLE (I10)
Elisabet Svenungsson, Stockholm, Sweden

15.10 Management of cardiovascular disease risk
Anisur Rahman, London, UK

15.30 Selected Oral Presentations

O26 Incidence and predictors of atherosclerotic vascular events in a multicentre inception SLE cohort
Murray Urowitz, Toronto, Canada

O27 Development and validation of a multivariable model for 5-year survival in Systemic Lupus Erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
Jingge Qu, Beijing, China

O28 Characteristics and risk factors of pulmonary embolism in patients with Systemic Lupus Erythematosus: A single-center cohort study
Jiulang Zhao, Beijing, China

16.00 Coffee break

16.30 Fishbowls – Topics
Is treat to target needed and achievable?
Pregnancy follow-up: How much is needed?
Steroids in lupus: Should 0 be the target?
What else, if HCQ fails or is not tolerated?

18.00 Guided Visit of Bruges for all participants
20.00 Gala Dinner at the Belfry
08.00  SLEuro General Assembly

Session 11: Antiphospholipid syndrome
Concert Hall
09.00  New pathophysiological mechanisms
Anisur Rahman, London, UK
09.20  Treatment of unusual APS manifestations
Jean-Charles Piette, Paris, France
09.40  Catastrophic APL syndrome: What is new? (I11)
Ricard Cervera, Barcelona, Spain
10.00  B-cell depletion therapy in APS (I12)
Nancy Agmon-Levin, Tel Hashomer, Israel
10.20  Selected Oral Presentation
O29  Determination of homogenous subgroups of antiphospholipid syndrome: A cluster analysis based on 509 cases
Yann Nguyen, Paris, France

10.30  Coffee break

11.00  Fishbowls – Topics
What is the optimal management of fatigue? SLE/APS: When to stop treatment?
How to improve adherence?
Do we really need patient reported outcomes?

09.00  Targeting B lineage cells in SLE: Current translational perspective
Thomas Dörner, Berlin, Germany
09.20  Platelets and SLE
Patrick Blanot, Bordeaux, France
09.40  Neutrophils and innate immunity in the pathogenesis of SLE (I13)
George Bertias, Heraklion, Greece
10.00  Selected Oral Presentations
O30  Complement deposition, C4d, on platelets is associated with vascular events and antiphospholipid antibodies in Systemic Lupus Erythematosus
Elisabeth Svensson, Stockholm, Sweden
O31  Integrative analysis reveals a molecular stratification of systemic autoimmune diseases
Guillermo Barturen, Granada, Spain
O32  Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways
Villja Oke, Stockholm, Sweden

12.00  A majority of lupus patients (will) need a biologic!
David Isenberg, London, UK
A minority of lupus patients (will) need a biologic!
Murray Urowitz, Toronto, Canada

13.00  Lunch break and Poster Viewing
13.30  Poster Presenters of P101 – P193 are invited to be at their posters for Q&A

14.00  Satellite Symposium
Session 13: Nephritis
15.00  Biopsy and repeat biopsy (I14)
David Jayne, Cambridge, UK
15.20  Outcome prediction
Farah Tamirou, Brussels, Belgium
15.40  Treatment
Frédéric Houssiau, Brussels, Belgium
16.00  Selected Oral Presentations
O33  Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
Ioannis Paroudis, Stockholm, Sweden
O34  Variants in BANK1 are associated with lupus nephritis
Karin Bolin, Uppsala, Sweden
O35  B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis
Richard Furie, New York, USA

Session 14: New targets
Chamber Music Hall
15.00  How to target pathogenic plasma cells in SLE?
Reinhard Voil, Freiburg, Germany
15.20  Hematopoietic stem cells
Dimtrios Bouspos, Athens, Greece
15.40  Selected Oral Presentations
O36  Low-dose IL-2 therapy modulates lymphocyte subsets that are involved in the regulation of germinal-centre reactions in patients with SLE
Jens Hunrich, Berlin, Germany
O37  MS049, a novel potent and selective inhibitor of toll-like receptors 7 and 8 (TLR 7/8)
Brian Sherer, Bellerica, USA
O38  Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
Daniel Strasser, Allschwil, Switzerland
O39  Targeting CD38 in Systemic Lupus Erythematosus
Lennard Ostendorf, Berlin, Germany

16.30  Closing Remarks
16.45  End of the 12th European Lupus Meeting
# Antiphospholipid syndrome (APS)

## P1 Antiphospholipid syndrome in Qatar: Epidemiological, clinical, and immunological characteristics
Nabeel Abdullah, Omar Alohaed, Fiaz Alam, Rowan Soleh, Abdurazzaq Poil, Abdreahim Siam, Eman Elsayed, Hani Abdulaziz, Samar Al Emadi (Qatar)

## P2 Difficulties in managing a patient with multi-organ damage in Systemic Lupus Erythematosus and a high risk of thrombotic events in antiphospholipid syndrome (case report)
Fanzu Cheileleva, Tatiana Reshetnya, Anastasiia Shumilova, Natalia Seredovkina, Maria Cherkasova, Tatiana Lisitsyna, Anastasia Borisova, Alexander Lila (Russian Federation)

## P3 Is there a relationship between lupus anticoagulant autoantibody and fatigue in JSE?
Sara Ganhão, Beatriz Silva, Mariana Rodrigues, Francsica Aguiar, Margarida Figueiredo-Braga, Iva Brita (Portugal)

## P4 Antiphospholipid syndrome in patients with acute myocardial infarction
Mikel Jordhan, Dorina Ruci, Joana Seiti (Albania)

## P5 Recognizing the disease, treating the patient: A mixed-method evaluation of care for the antiphospholipid syndrome (APS) in The Netherlands
Mirthe Klein Haneveld, Cora Lennem, Tammo Brunekeef, Marc Bijl, Gerard Jansen, Karina Leeuw, Julie Sparing, Marnen Limper, on behalf of the ARCH study group (The Netherlands)

## P6 Rituximab efficacy in CAPS
Olena Yakymenko, Viktoriya Vasylyets, Vladimir Savytskyi, Nataly Tikhonchuk (Ukraine)

## P7 Rivaroxaban may trigger catastrophic antiphospholipid syndrome
Romain Stammier, Paul Legendre, Patrice Cocoub, Philippe Blanche, Jean Charles Pette, Nathalie Costedoat-Chalumeau (France)

## P8 Refractory thrombocytopenia in a patient with Systemic Lupus Erythematosus and secondary antiphospholipid syndrome
Rita Torres, Maria Jado Gonçalves, Nuno Gonçalves, Santiago Monica, Agna Neto, José Maroana, Manuela Costa, Fernando M. Pimentel-Santos, Jaime C. Branco (Portugal)

## P9 Validation of the adjusted Global Antiphospholipid Syndrome Score and correlation with extra-criteria manifestations
Omer Uludag, Murat Bektas, Erhan Cene, Yasemin Sahinkaya, Ahmet Gui, Lale Ocal, Murat Inanc, Bahar Artim-Esen (Turkey)

## P10 Antiphospholipid antibodies associated extra-criteria clinical manifestations should not be ignored
Jiuliang Zhao, Chaojun Hu, Can Huang, Xinping Tian, Mengtao Li, Xiaofeng Zeng (China)

## P11 Early efficient anticoagulation improves the long-term prognosis in patients with Antiphospholipid Syndrome associated Portal Vein Thrombosis
Jiuliang Zhao, Hanxiao You, Xinping Tian, Mengtao Li, Xiaofeng Zeng (China)

## P12 Serum levels of soluble ST2 and their association with microparticles and disease activity in systemic lupus erythematosus
Karen Alvarez, Manuela Osorio, Tulio Lopera, Karen Dubois-Camacho, Marcela A. Hermosa, Gloria Vázquez (Chile)

## P13 Assessing the ability of Anti-Ctq antibody measurement to predict a flare of Lupus Nephritis
Sameer Bahal, Dev Pyne, Roivanda Rajakarier, Myles Lewis, Angela Pakozdi, Andrea Cove-Smith (UK)

## P14 Microarray analysis identifies Anti-CpG antibodies to be strongly associated with SLE and Lupus Nephritis
Tammo Brunekeef, Maarten Limper, Linda Mathsson-Alm, Jorge Dias, Joap van Laar, Ina Hoefer, Saskia Haatjema, Henly Otten (The Netherlands)

## P15 Anti-carbamylated proteins’ levels are negatively correlated with circulating effector T-cells in a cohort of patients with Systemic Lupus Erythematosus
Silvia Piantoni, Ilaria Cavazzana, Francesco Polatti, Stefania Masneri, Roberta Ottaviani, Micaela Fredi, Franco Franceschini (Italy)

## P16 The combined type-I interferon and neutrophil gene scores identify highly active Systemic Lupus Erythematosus patients and performed better than classical serological markers
François Chasset, Camillo Ribi, Marten Trendelenburg, Uyen Huynh-Do, Pascole Roux-Lombard, Delphine S. Courvoisier, Carlo Chizzolino (Switzerland)

## P17 Anti-neuronal antibodies in patients with Systemic Lupus Erythematosus: Prevalence, clinical as associations and searching for a specific target
Elisabetta Chessa, Maria Maddalena Angioni, Silvia Pinna, Mattia Cangia, Alberto Floris, Elias Manca, Giulia Corda, Lorena Lorefice, Gian Luca Ferri, Cristina Cocco, Alessandro Mathieu, Alberto Cauli, Matteo Piga (Italy)

## P18 Presence of rheumatoid factor was associated with a decreased risk of Lupus Nephritis in patients with Juvenile Systemic Lupus Erythematosus
Yasmin Mahfouz, Anastasia Vasiliki Madenidou, Oliver Chang, Farah El-Sharmouby, Charlene Foley, Coziana Curin (UK)

## P19 Autoantibody profile analysis in SLE patients

## P20 Investigation of possible pathogenic autoantibodies in membranous Lupus Nephritis
Filipa Farinha, Ruth J. Pepper, Chris Wincup, Alan Salama, David A. Isenberg, Anisur Rahman (UK)
P22 Anti-carbamylated protein antibodies in Systemic Lupus Erythematosus: Clinical and serological associations
Micaela Fredi, Ilaria Cavazzana, Francesco Poliatti, Michele Boldrini, Silvia Piantoni, Rajesh Kumar, Roberto Ottoviani, Angela Tincani, Franco Franceschini (Italy)

P23 Longitudinal antinuclear antibody (ANA) seroconversion in Systemic Lupus Erythematosus: A prospective study of Swedish cases with recent-onset disease
Martina Fredlund, Jonas Wetterö, Charlotte Dahle, Orjan Dahlström, Thomas Skogh, Johan Rönnefeld, Christopher Sjowall (Sweden)

P24 Correlation between serum autoantibodies and clinical manifestations in jSLE
Sara Ganhdão, Francisca Aguiar, Mariana Rodrigues, Iva Brito (Portugal)

P25 Disrupted place cell properties in the hippocampus represent the neural substrate for cognitive impairment in neuropsychiatric lupus
Patricia T. Huerta, Joshua J. Strahl, Tomás S. Huerta (USA)

P26 Serum BAFF and APRIL as candidate biomarkers in Systemic Lupus Erythematosus (SLE): A prospective follow-up study
Selma Sari, Suzan Çinar, Bahar Artim Eren, Ahmet Gül, Lalı Öcal, Gunnar Deniz, Murat Inanç (Turkey)

P27 Myxovirus resistance protein A is a useful additional histological marker for Cutaneous Lupus Erythematosus
Wietse M. Lambers, Gilles F.H. Diercks, Femke M. Homan, Berber Doornbos-van der Meer, Hendrika Bootsma, Johanna Westra, Karina de Leeuw (The Netherlands)

P28 Decreased plaque size in Systemic Lupus Erythematosus is associated with up-regulation of type I interferon proteins
Petrus Linge, Lina Wirestam, Sabine Arve, Robin Kahn, Andreas Jansen, Anders Bengtsson (Sweden)

P29 Clinical relevance of DFS70 antibodies at a community hospital
Ana Rita Moia, Ana Sofia Pinto, Joana Ferreira, Cláudia Vez (Portugal)

P30 A custom-made microarray for detection of autoantibodies in Systemic Lupus Erythematosus
Linda Mathsson-Alm, Kerstin Anger, Jorge Dias, Henny Otten, Tammo Poonse-van der Meer, Hendrika Bootsma, Johanna Westra, Karina de Leeuw (The Netherlands & Germany)

P31 Anti-Domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development
Thomas McDonnell, Filipa Farinha, Charis Pericleous, Maura Griffin, Andrew Nicholaides, Sara Croca, Ian Giles, Anisur Rahman (UK)

P32 Assessment of left ventricular using speckle tracking echocardiography and its relationship with insulin resistance in non-diabetic patients with SLE
Claudia Mendezo-Pinto, Pamela Munguia-Reajpazo, Liliana Aquino, Adalberto Ramirez-Hernandez, Roberto Berra-Romani, Aurelio Lopez-Colombo, Maria Garcia-Carrasco (Mexico)

P33 Cytokine and autoantibody profiles during treatment with belimumab in patients with Systemic Lupus Erythematosus
Ioannis Parodis, Emil Åkerström, Christopher Sjowall, Azita Sohrabian, Andreas Jansen, Alvaro Gomez, Martina Fredlund, Agnete Zickert, Anders A. Bengtsson, Johan Rönnefeld, Iva Gunnarsson (Sweden)

P34 Urinary proteomics In Lupus Nephritis - Prospective study in a tertiary care center
Ramesh Ramamoorthy, Ragavendran, Kumudha Manoharan, Balameena Kumar (India)

P35 Measuring dsDNA antibodies in the elderly: Positive results rarely indicate lupus
Anu Desai, Benjamin Rhodes (UK)

P36 Using machine learning to identify and stratify patients with juvenile-onset SLE
George Robinson, Junjie Peng, Anna Rodziszewska, Chris Wincup, Hannah Peckham, Meena Noja, David Isenberg, Yiannis Ioannou, Ines Pineda-Torres, Caziana Curtin, Elizabeth Jury (UK)

P37 Non-invasive biomarkers of disease activity in Systemic Lupus Erythematosus
Guillermo Ruacho, Ronald Lira-Juniar, Iva Gunnarsson, Elisabet Svenungsson, Elisabeth Almer Boström (Sweden)

P38 Descriptive analysis of patients positive for anti-PCNA antibodies
Beatriz Samões, Maria Figueiredo, Diogo Fonseca, Miguel Guerra, Romana Vieira, Taciana Videira, Joana Abelha-Alexio, Patricia Pinto, Ana Paula Cruz (Portugal)

P39 Longitudinal changes of cerebral white matter tissue microstructure in early-onset Systemic Lupus Erythematosus
Ettore Silvagni, Francesca Inglese, Alessandra Bortoluzzi, Alfredo Revenaz, Massimo Borrelli, Margretr Steup-Buekmann, Tom Huizinga, Jeroen De Bresser, Ilmar Ronen, Enrico Fainardi, Marcello Govoni, Emir Ercan (The Netherlands & Italy)

P40 Promising salivary protein biomarkers in Korean patients with Systemic Lupus Erythematosus
Chang-Hee Suh, Ju-Yang Jung, Wook-Young Baek, In-Ok Son (Korea)

P41 Predicting autoimmune connective tissue diseases: Three year follow up of an At Risk cohort identifies late progression and biomarkers to predict need for therapy
Sabih-Ul Hassan, Katie Dutton, Zoe Wigston, Ade Alase, Md. Yuzafud Md. Yusof, Edward M. Vitol (UK)

P42 Disease activity, impaired iron transport and failed sequestration: A novel mechanism for anaemia in Systemic Lupus Erythematosus
Chris Wincup, Thomas McDonnell, George Robinson, Filipa Farinha, Anna Rodziszewska, David Isenberg, Anisur Rahman (UK)

P43 Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement and fatigue in SLE
Kristoffer Alexander Zervides, Andreas Jern, Jessica Nystedt, Petra Nilsson, Pia C. Sundgren, Birgitta Guzle, Anders A. Bengtsson, Andreas Jonsen (Sweden)
P44 Urticarial vasculitis in childhood onset Systemic Lupus Erythematosus
Reem Abdwani, Safiya Al Abrawi, Ahmed Al Kaimzari, Ibraheem Al Zawkani, Buthaina Al Maslihi (Oman)

P45 ANA positivity in IgA nephropathy: Is Systemic Lupus Erythematosus coming up?
Fausta Catapona, Benedetta Fabbriozzo, Elena Mancini (Italy)

P46 Case report: A patient with human immune deficiency virus mimicking Systemic Lupus Erythematosus
Neslihan Gökken, Hacer Kaya, Fatma Tunçer, Ayten Yaziç, Ayse Çelife (Turkey)

P47 Cognitve impairment in JSL - The role of inflammation
Beatriz Silva, Sara Ganhão, Mariana Rodrigues, Francisca Aguiar, Iva Brita, Margarida Figueiredo-Braga (Portugal)

P48 Are new 2019 SLE EULAR/ACR classification criteria useful in patients with Rhupus?
Beatriz Frade-Sosa, Javier Navarro, Tarek Salman-Monte, Vera Ortiz-Santamaria, Vicente Torrente-Segarra, Ivan Castelvi, Berta Magallares, Raul Castellanos-Moreira, Delia Reina, Sonia Miguez, Meritxell Salles, Maria García Manrique de la Lara, Sonia Ordóñez, Elena Riera, Jose A. Gómez-Puerto, on behalf of the CAPITCAT-MAS Study Group (Spain)

P49 Severe infection prior to diagnosis of Systemic Lupus Erythematosus (SLE) is associated with disease classification criteria
Yu Deng, Anh Chung, Abel Kho, Yuan Luo, Rosalind Ramsey-Goldman, Theresa Walunas (USA)

P50 Difficult to diagnose SLE manifestations associated with cardiac arrest, myocarditis, chronic pericarditis, polyneuropathy
Tatjana Žekić (Croatia)

P51 Trends in mortality in Systemic Lupus Erythematosus: An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007-2016
Himashi Anver, Shirish Dubey, James Fox (UK)

P52 The relationship of vitamin D levels with disease activity in Systemic Lupus Erythematosus
Lambros Athanassiou, Ifigenia Kostoglou, Pavlos Tsokirdis, Akaterini Tzanavari, Irini Devetzi, Marina Gatsiou, Michael Koutsilieris, Panagiotsis Athanassiou (Greece)

P53 Acute West Nile virus infection in an SLE patient - Diagnostic and therapeutic challenges
Pavlos Tsokirdis, Lambros Athanassiou, Irini Devetzi, Maria Mavroudi, Marina Gatsiou, Dimitrios Pantelidis, Akaterini Tzanavari, Panagiotsis Athanassiou (Greece)

P54 Incidence of skin cancer in Systemic Lupus Erythematosus compared with Systemic Sclerosis and general population
Ilaria Cavazzana, Marta Fusano, Micaela Fiedi, Piergiacomo Calzavara-Pinton, Franco Franceschini (Italy)

P55 Influence of dietary fibre and short-chain fatty acids on the pathogenesis of Systemic Lupus Erythematosus
Alexandra Eichhorst, Anna-Lena Schäfer, Reinhard Edmund Voll, Nina Chevalier (Germany)

P56 Rhupus Syndrome in a tertiary hospital
Isabel Martínez-Cordellat, Roxana González-Mazarío, Marta De-la-Rubia-Navarro, Cristobal Pavez-Perales, Samuel Leal-Rodriguez, José Iñigo-Cortés, Inmaculada Chameto-Verdejo, Elena Grau-García, Cristina Alcalzíz-Escandell, Jorge Juan Fragio-Gil, Luis González-Puig, Rosa Negueroles-Albixech, José Eloy Oiler-Rodríguez, Francisco Miguel Ortiz-Sanjuán, Elviro Vicens-Bernabeu, Carmen Nájera-Herranz, Inés Cánovas-Olmos, José Andrés Román-Ivora (Spain)

P57 Smoking and primary chronic cutaneous lupus: Who are the most vulnerable?
Cristina Drenkard, Laura Aspey, Charles Helmick, Goobin Bao, S. Sam Lim (USA)

P58 Systemic Lupus Erythematosus in native sub-Saharan Africans: A systematic review and meta-analysis
Mickael Essauma, Jan René Nkeck, Francky Teddy A. Endomboa, Jean Joel Bigna, Madeleine Singwe-Ngandeu, Eric Hacklou (France & Cameroon)

P59 Predictors of renal survival in a cohort of patients with Lupus Nephritis with more than 30 years of follow-up
Filipa Faninha, Ruth J. Pepper, Daniel G. Oliveira, Thomas McDonnell, David A. Isenberg, Anisur Rahman (UK & Portugal)

P60 Immune status to measles in a U.S. Lupus clinic serving patients with limited access to healthcare
Alice Fike, Abhimanyu Amarnani, Yanira Ruiz-Perdomo, Sarfaraz Hasni, James Katz (USA)

P61 Does celiac disease diagnosis modify the game rules in lupus patients? A 7 case series report
Jorge Juan Fragio-Gil, Roxana Gonzalez-Mazarío, José Iñigo Cortés, Elena Grau-García, Luis González-Puig, Francisco Miguel Ortiz-Sanjuán, Samuel Leal-Rodriguez, Isabel Martínez-Cordellat, Rosa Negueroles-Albixech, José Eloy Oiler-Rodríguez, Marta De-la-Rubia-Navarro, Inmaculada Chameto-Verdejo, Cristina Alcalzíz-Escandell, Cristóbal Pavez-Perales, Elviro Vicens-Bernabeu, Carmen Nájera-Herranz, Inés Cánovas-Olmos, José Andrés Román-Ivora (Spain)

P62 Poly-autoimmunity frequency in SLE patients from a tertiary hospital
Samuel Leal-Rodriguez, Elena Grau-García, Roxana González-Mazarío, Marta De-la-Rubia-Navarro, Cristóbal Pávez-Perales, Isabel Martínez-Cordellat, Carmen Nájera-Herranz, Rosa Negueroles-Albixech, José Eloy Oiler-Rodríguez, Francisco Miguel Ortiz-Sanjuán, Elviro Vicens-Bernabeu, Cristina Alcalzíz-Escandell, Inés Cánovas-Olmos, Inmaculada Chameto-Verdejo, Jorge Juan Fragio-Gil, Luis González-Puig, José Iñigo-Cortés, José Andrés Román-Ivora (Spain)

P63 Abnormal distribution of CD27* IgD* unswitched and CD27* IgD* switched memory B cells in SLE patients exposed to organic solvents
Carolina Hurtado, Diego Rojas-Gualdrón, Elisa María Vásquez-Trespalacios, Ricardo Pineda, Scott Jenks, Gloria Vásquez, Iñaki Sanz (Columbia & USA)

P64 Mortality in patients with Systemic Lupus Erythematosus and neuropsychiatric symptoms
Rory Monahan, Rolf Franzcek, Jeroen Eekenboom, Huub Middelhoek, Liesbeth Beear-van de Voorde, Gisela Terwindt, Nic van der Wee, Frits Rosendaal, Tom Huizinga, Margreet Kloppeen, Margreet Steup-Beekman (The Netherlands)
P65  Systemic Lupus Erythematosus and caffeine consumption: Impact on phenotype and disease activity
Valeria Oreifice, Fulvia Ceccarelli, Ramona Lucchetti, Giulia Olivieri, Enrico Cipriano, Francesco Natalucci, Carlo Perricone, Francesca Romana Spinelli, Guido Valesini, Fabrizio Conti (Italy)

P66  Utilization of Geographic Information System (GIS) mapping to assess dissemination of a lupus community based health awareness model
Karen Manero-Cuevos, Daniel L. Erickson, Anh Chung, Joan S. Chmiel, Courtnie Philip, Candace Feldman, Patricia Canessa, Rosalind Ramsey-Goldman (USA)

P67  Jaccoud’s Arthropathy in Systemic Lupus Erythematosus: A case series of 52 Brazilian patients
Mittermayer Santiago (Brazil)

P68  A diet rich in wheat alpha-amylase/trypsin inhibitors (ATIs) enhances disease progression in the MRL-Fas(lpr) mouse model of Systemic Lupus Erythematosus
Myriam Meineck, Simone Boedecker, Victor Zevailles, Andreas Schwarting, Detlef Schuppan, Julia Weinmann-Menke (Germany & USA)

Family planning, fertility, pregnancy and neonatal care

P69  Risk factors for adverse pregnancy outcome in patients with SLE
Çiğdem Çetin, Tuğba Saraoğlu-Sivrkoz, Muge Ateş-Tikza, Yasemin Yağcınkaya, Ahmet Gül, Lale Öcal, Murat İnaç, İbrahim Kalelioglu, Bahar Artim-Esen (Turkey)

P70  Increased work loss during pregnancy in women with Systemic Lupus Erythematosus compared to matched healthy controls
Birgit Blomjous, Mariëke ter Wee, Carolien Abheiden, Alexandre Voskuyl, Johanna de Vries, Irene Buttink (The Netherlands)

P71  Systemic Lupus Erythematosus and pregnancy – 10 years’ experience from a Portuguese tertiary center
António Braga, Jorge Braga, Carlos Vasconcelos (Portugal)

P72  Knowledge and use of contraceptive methods in Portuguese women with Systemic Lupus Erythematosus
Luisa Brites, Stefanie Silva, Laura Andreoli, Luis Inês (Portugal)

P73  The relationship between pregnancy, disease activity and adverse pregnancy outcomes in Systemic Lupus Erythematosus
Çiğdem Çetin, Tuğba Saraoğlu-Sivrkoz, Muge Ateş-Tikza, Sibel Zorali, Aysenur Erosy, Yasemin Yağcınkaya, Ahmet Gül, Lale Öcal, Murat İnaç, İbrahim Kalelioglu, Bahar Artim-Esen (Turkey)

P74  Complement variations in Systemic Lupus Erythematosus pregnancies
Francesca Cisafulli, Laura Andreoli, Matteo Filippini, Micaela Fredi, Maria Chiara Gerard, Roberto Gorla, Maria Grazia Lazzaroni, Cecilia Nolli, Marco Taglietti, Andrea Lojacono, Sonia Zatti, Franco Franceschini, Angela Tincani (Italy)

P75  Anti-SSA/Ro positivity and the risk of congenital heart block: Obstetric and fetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases
Micaela Fredi, Maria Gerosa, Laura Andreoli, Tamara Vojanic, Cecilia Beatrice Chighizola, Federico Gazzola, Andrea Lojacono, Sonia Zatti, Laura Trespaldi, Enrico Ferrazzi, Roberto Caporali, PierLuigi Meroni, Franco Franceschini, Angela Tincani (Italy)

P76  Low dose aspirin to prevent pre-eclampsia in SLE pregnancies – Counselling helps to realize our full potential
Isabell Haase, Matthias Schneider, Ralph Brinks, Rebecca Fischer-Betz (Germany)

P77  Evaluation of disease activity at conception in a prospective cohort of SLE pregnancies
Maddalena Larosa, Vanessa Ochirin, Anna Ghirardello, Margherita Zen, Marielle Gatto, Luca Iaccarino, Andrea Doria (Italy)

P78  Outcomes of Systemic Lupus Erythematosus pregnancies and associated factors in sub-Saharan Africa: A systematic scoping review
Mickael Essouma, Jan René Nkeck, Jean Joel Bigna, Grâce Anita Nkora, Stéphane Rolandison, Eric Houhula (Cameroon, France & Madagascar)

P79  Predictors of adverse neonatal outcome during the pregnancy of women with antiphospholipid syndrome in the French GR2 prospective study
Anne Muraressa, Goëlle Guettrot-Imbert, Véronique Le Guern, Francois Maurier, Patrick Jego, Estibaliz Lazor, Alban Deroux, Mélodie Le Besnerois, Odile Souchaud-Debouverie, Pauline Orquevaux, Catherine Deneux-Tharaux, Nathalie Costedoat-Chauveau, and the GR2 study group (France)

P80  Sexual health in Systemic Lupus Erythematosus: A cross-sectional analysis
Agna Neto, Rita Torres, Carina Lopes, Filipo Moura, Jaime Branco, Manuela Costa (Portugal)

P81  15 years experience in follow-up of autoimmune diseases in a multidisciplinary unit
Esther Ruiz-Lucea, Oihane Ibarraungoiti, Natalia Rivera, Jenaro Oroa, Eduardo Ucar, Ana Inxurute, Itziar Calvo, David Montero, Lucia Vega, Carmen Garcia, Clara Perez, Olaia Fernandez, Ignacio Torre, Juan Blanco, Eva Galindez, M.J. Allande, Iligo Gorostiza, Eduardo Cuende, Maria Luz Garcia (Spain)

P82  Anti-phospholipid antibodies and renal involvement are the main associated factors with adverse pregnancy outcomes in patients with Systemic Lupus Erythematosus - A long-term longitudinal study in Southern Sweden
Muna Saleh, Andreas Jönsen, Anders Bengtsson, Christopher Sjöwall, Michele Compagno (Sweden)

P83  A pre-pregnancy counselling pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome: The effect on maternal and fetal pregnancy complications and the course of disease - A retrospective cohort study
Merlijn Wind, Maike Hendriks, Marijke Sueters, Onno Teng (The Netherlands)

P84  Lupus and pregnancy in Uruguay: Successful outcomes in an integrated care unit
Valentina Zubiaurre, Carolina Delos Santos, Mariana Cora, Valentin Gonzalez, Sebastián Rosano, Ricardo Silvarillo, Leonardo Sosa (Uruguay)
P85  The IRF5 (rs729302) polymorphism is a genetic risk factor for Systemic Lupus Erythematosus in Algerian patients
Ines Allam, Aldjia Lamri, Sihem Ouloucrouz, Mohamed Saidani, Reda Djjijik (Algeria)

P86  The NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in Systemic Lupus Erythematosus
Sabine Arve, Petrus Linge, Lina Olsson, Dog Leonard, Christopher Sjöwall, Martina Fredlund, Iva Gunnarsson, Elisabet Svennungsson, Helena Tysdén, Andreas Jønsen, Robin Kahn, Åsa Johansson, Lars Rönnblom, Rikard Holmdahl, Anders Bengtsson (Sweden)

P87  Impact of APO1 polymorphism on Lupus Nephritis
Carole Burger, Celine Noraj, Nathalie Costedoat-Chalumeau, Aurélie Hummel, Julie Chezel, Eric Therve, Alexandre Karras (France)

P88  Cell free DNA bacterial sequences in patients with Lupus Nephritis differ from patients with IgA nephropathy and membranous nephropathy
Bartosz Foroncewicz, Krzysztof Mucha, Arkadiusz Gladki, Barbara Moszczuk, Natalia Krata, Marta Monticolo, Urszula Zielenkiewicz, Piotr Zielenkiewicz, Leszek Pączek (Poland)

P89  Epigenome-wide association study reveals differential DNA methylation in Systemic Lupus Erythematosus patients with a history of ischemic heart disease
Juliana Imgenberg-Kreuz, Christopher Sjöwall, Martina Fredlund, Iva Gunnarsson, Elisabet Svennungsson, Dog Leonard (Sweden)

P90  Genetic risk, smoking and the development of Systemic Autoimmune Rheumatic Disease
Henrik Christian Bidstrup Leffers, David Westergaard, Karina Banasik, Søren Jacobsen (Denmark)

P91  The development and validation of a polygenic risk score for myocardial infarction in SLE
Sarah Reid, Johanna K. Sandling, Andrei Alexsson, Pascal Pucholt, Christopher Sjöwall, Karoline Lerang, Andreas Jønsen, Iva Gunnarsson, Ann-Christine Syvänen, Lars Rönnblom, Dog Leonard (Sweden & Denmark)

P92  Genomic convergence of locus-based GWAS meta-analysis identifies DDX11 as a novel Systemic Lupus Erythematosus gene
Mohammad Saeed, Alejandro Ibáñez-Costa, Alejandra María Patiño-Trives, María Ángeles Aguirre, Chary López-Pedreña (Pakistan & Spain)

P93  Analysis of low-frequency and rare variants in Swedish SLE Patients with Lupus Nephritis
Sule Yavuz (Sweden)

P94  TLR7 and TLR8 differentially activate the IRF and NF-κB pathways in specific cell types to promote inflammation
Andrew T. Bender, Evgeni Tzvetkov, Albertina Pereira, Siddha Kasar, Melinda Przetak, Shinji Okitsu, Jaromir Vlach (USA)

P95  Costimulatory molecules on CMV-specific T-cells in CMV IgG+ patients with Systemic Lupus Erythematosus
Artje Savidis, Benjamin Wilde, Andreas Kribben, Oliver Witzke, Sebastian Dollf (Germany)

P96  The regulation and pharmacological modulation of immune complex induced production of type III IFN by plasmacytoid dendritic cells
Karín Hjortan, Niklas Hagberg, Pascal Pucholt, Olof Berggren, Maja-Leena Eloranta, Lars Rönnblom (Sweden)

P97  Deficiency of marginal-zone B cells in peripheral blood of SLE patients in clinical remission or low disease activity state in a long-term study
Zbynek Hrncir, Doris Vokurkova, Marcela Drahossova, Tomas Soukup (Czech Republic)

P98  Neutrophils in lupus: A new phenotype
Sondrine Huot, Cynthia Lofmanne, Martin Pelletier, Philippe Tessier, Eric Boilard, Paul R. Fortin, Marc Pouliot (Canada)

P99  Effector DN2 B cells are expanded in a mixed ancestry Colombian SLE patient population
Carolina Hurtado, Diego Rojas-Gualdron, Ricardo Piedra, Scott Jenks, Gloria Vasquez, Iñaki Sanz (Colombia & USA)

P100 Proportions of B cell subsets are altered in incomplete lupus erythematosus patients and correlate with interferon score and IgG levels

P101 Hydroxychloroquine suppresses IFN-inducible genes and BAFF in patients with incomplete and new onset Systemic Lupus Erythematosus
Wietse Lambers, Johanna Westra, Hendrika Bootsma, Karina de Leeuw (The Netherlands)

P102 Senescence of renal resident cells is associated with impaired renal function in Lupus Nephritis
Gaëlle Tilman, Selda Aytin, Christine Galant, Farah Tamirou, Frédéric Houssiau, Bernard Lauwerys (Belgium)

P103 Aberrant DNA damage response of B cell populations in Systemic Lupus Erythematosus
Theodora Manolakou, Aggelos Banos, Anastasia Filia, Antigone Pieta, Panayotis Verginis, Dimitrios Boumpas (Greece)

P104 Correlation between interstitial CD8+ T cell infiltration and fibrotic processes in a mouse model of Lupus Nephritis
Pauline Montigny, Aurélie Degroof, Davide Brusa, Frédéric Houssiau, Bernard Lauwerys (Belgium)
P105 Expression diversity of interferon-stimulated genes in peripheral blood cells from patients with Systemic Lupus Erythematosus
Kanwal Siddiqi, Søren Jacobsen (Denmark)

P106 Pentameric, but not monomeric C-reactive protein, limits the snRNP-immune complex triggered type I interferon response: Implications for lupus pathogenesis
Cecilia Svaneberg, Helena Enrocsson, Klara Martinsson, Lawrence Potempa, Ibraheem Rajab, Jonas Wetterer, Marie Larsson, Christopher Sjowall (Sweden & USA)

P107 Interferon-induced metabolic perturbations shape the inflammatory status of human monocytes: Implications for innovative therapeutic engineering in SLE autoimmunity
Chrysoula Stathopoulou, Vassilis Ntossis, Aggelos Banos, Katerina Gkinizmanaki, Antonis Myridakis, Christina Adamichou, Prodromas Sidirooulos, George Berisias (Greece & UK)

P108 Oxidative stress in NK cell and its correlation with expression of killer immunoglobulin receptors in SLE patients
Archana Bhatnagar, Ankit Tandon (India)

P109 Mental disorders in Systemic Lupus Erythematosus and antiphospholipid syndrome patients
Anastasia Borisova, Fariza Cheldieva, Tatiana Lisitsyna, Tatiana Reshetnyak, Dmitry Veltishev, Olga Seravina, Oksana Kovalevskaya (Russian Federation)

P110 Lupus Europe – Exercise program for lupus patients
Jeanette Andersen, Alain Cornet, Kirsi Myllylä, Anne Charlet, Annemarie Sluijmers, Helga Ovens (UK, Denmark & Switzerland)

P111 Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Russian patients with Systemic Lupus Erythematosus
Elena Aseeva, Lyubov Vorobyova, Sergey Soloviev, Svetlana Glukhova (Russian Federation)

P112 Lupus Nephritis in males: Clinical and histological profile, disease course and management - Results from a Nephrology Clinic in Sri Lanka
Duminda Basnayake, Abdul Wazil, Nishantha Nanayakkara, Mohommed Shafraz (Sri Lanka)

P113 Online case-based education substantially improved rheumatologists’ confidence and competence in managing SLE and selecting appropriate treatments
Elaine Bell, Robert McCarthy, Ronald van Vollenhoven (UK, USA & The Netherlands)

P114 Evaluation of neuropsychiatric involvement and psychometric status in pediatric Systemic Lupus Erythematosus (SLE)
Chhloe Keith-Jopp, Kirstie Coxon, Dimitra Nikoletou, Dylan Morrissey, Debasish Pyne (UK)

P115 The clinical features and outcome of Lupus Nephritis patients presenting with Myocarditis: A single center experience
Nouran Eshak, Shaimaa Shoeta, Fatma Fayad, Asmaa Beltagy, Mai Morsy, Mahmoud Abdelnabi (Egypt & USA)

P116 Outcomes and safety of Rituximab use in Systemic Lupus Erythematosus – A single-centre analysis
Daniel G. Oliveira, Raquel Faria, Flávia Pereira, Luciana Faria, Ana Campar, Mariana Brandão, Isabel Almeida, Antônio Marinho, Fátima Farnha, Carlos Vasconcelos (Portugal)

P117 Rituximab therapy for Primary Sjögren’s syndrome - A retrospective single-centre study
Mariana Figueiras, Filipa Sousa, Mariana Brandão, Daniel Oliveira, Raquel Faria, Ana Campar, Isabel Almeida, Antônio Marinho, Fátima Farnha, Carlos Vasconcelos (Portugal)

P118 Patient perceptions of physical activity in Systemic Lupus Erythematosus - An explorative qualitative study
Chhloe Keith-Jopp, Kirstie Coxon, Dimitra Nikoletou, Dylan Morrissey, Debasish Pyne (UK)

P119 Medication adherence is influenced by resilience in patients with Systemic Lupus Erythematosus
Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Sandra Campos-Rivera, Socorro Méndez-Martínez, Mario García-Carrasco (Mexico)

P120 Potential and prognostic factor for belimumab-free remission in SLE patients: Single-center retrospective analysis
Takehiro Nakai, Yukihiro Ikeda, Ayako Kitada, Masei Sudo, Hiromichi Tamaki, Kenichi Yamaguchi (Japan)

P121 Identification and active management of secondary adrenal Insufficiency in SLE reduces risk of relapse
Benjamin Rhodes, Haroon Ahmad, Sarah Logan, Elizabeth Rankin, Peter Hewins (UK)

P122 What do patients with lupus and Sjögren’s syndrome know about cardiovascular risk?
Elvira Chocano Navorro, George Robinson, Kirsty Waddington, Thomas McDonnell, Chris Wincup, Lucía Martín-Gutierrez, Annalisa Maggio, Eve McLaughlin, Lizzy Rosser, David Isenberg, Anastasia Kalea, Coziana Ciurtin, Inês Penedo-Torralba, Elizabeth Liu (UK)

P123 Novel approaches to systemic rheumatic diseases
Sara Salvucci, Antonella Festa, Emanuele Filippini, Lucia Manfredi, Maria Giovanna Danielli, Armando Gabrielli (Italy)

P124 The impact of the New American College of Cardiology/American Heart Association (ACC/AHA) definition of hypertension on atherosclerotic vascular events in Systemic Lupus Erythematosus
Konstantinos Tselios, Dafna D. Gladman, Jiandong Su, Murray B. Urowitz (Canada)

P125 Internet-based exercise therapy in patients with Systemic Lupus Erythematoses - Systemic Lupus Erythematoses Exercise Program (SLEEP)
Simone Boedecker, Elmo Neuberger, Ketlo Philippi, Anna Hazenbiller, Arndt Weinmann, Andreas Schwarting, Simon Penkies, Julia Weismann-Menke (Germany)
P126 Tolerability, efficacy and adherence: What do lupus patients think about treatment?
Elviro Chocano Navarro, George Robinson, Lucia Martin Gutierrez, Thomas McDonnell, Kirsty Waddington, Elizabeth Ju, Coziana Ciurtin, Chris Wincup (UK)

New therapies/Biologics and SLE drug pipeline

P127 Long-term effects of combined B-cell immunomodulation with Rituximab and Belimumab in severe, refractory SLE: Two year results

P128 Efficacy of intravenous belimumab in children with Systemic Lupus Erythematosus with markers of high disease activity: A cross-trial comparison with adult belimumab studies
Damon L. Bass, Mohamed Okily, Anne Hammer, Beulah Ji, David Roth, Holly Quasny (USA & UK)

P129 Adoptive transfer of autologous cytotoxic T lymphocytes against Epstein-Barr virus (EBV-CTL) in patients with systemic lupus (SLE): Preliminary results
Antoine Enfrein, Béatrice Clémentieux, Saraya Saiagh, Henri Vié, Mohamed Hamidou (France)

P130 Treatment of SLE with the immunoproteasome inhibitor KZR-616: Results from the first 4 cohorts of the MISSION Study, an open-label Phase 2b dose escalation trial
Richard Furie, Samir V. Parikh, Adonis Maïquez, Amber Khan, Orlando Moreno, Miguel Soneira, Christopher Kirk, Darrin Bomba, Kenneth Harvey, Mary Katherine Farmer (USA)

P131 Belimumab in the treatment of 38 Portuguese SLE patients: A real-life multicentric study
Bruno Fernandes, Miguel Bernardes, Sofia Barreira, João Eunico Fortesca, Margarida Cunha, Maria José Santos, Nuno Gonçalves, Ana Lúcia Fernandes, Joana Rodrigues, Tomás Fonse, Lúcia Costa (Portugal)

P132 Design of an adaptive, phase 2, placebo-controlled, dose-ranging study to assess the efficacy and safety of AMG 570 in subjects with active SLE and inadequate response to standard of care therapy
Lei Zhou, Hui Wang, Tony Jiang, Sandra Garces, Laurence E. Cheng, Rob Lenz, Primal Kaur (USA)

P133 Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)
Issac Hokin, Sana Mujahid, Aaron C. Daugherty, Timothy S. Heuer (USA)

P134 A preclinical double-blinded, randomized, controlled, multicenter trial (pRCT) on Jak1/Jak2 inhibition in Lupus Nephritis
Yutian Lei, Bettina Sehnert, Reinhard E. Voll, Conxita Jacobs-Cachá, María Jose Soler, Maria D. Sanchez-Niño, Alberto Ortiz, Roman D. Bülow, Peter Boor, Hans-Joachim Anders (Germany & Spain)

P135 A Phase I, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of MS5049, a dual antagonist of TLR7/8, in healthy subjects
Andreas Port, Lena Klopp-Sulze, Jomie Shaw, Elizabeth Hussey, Nadra Mammasse, Ying Zhang, Angelika Bochmann, Christian Reh, Kosalaram Goteti (France & Germany)

P136 SLEDAI response prediction to Belimumab therapy by baseline levels of BLyS, APRIL and CD8+ effector memory T-cells
Francesca Regola, Silvio Plantoni, Laura Andreoli, Torsten Lowin, Paolo Airò, Franco Franceschini, Angela Tincani, Georg Pongratz (Italy & Germany)

P137 De novo Lupus Nephritis during belimumab treatment
Ioannis Parodis, Edward M. Vitoi, Andreas Jansen, Sabih-Ul Hassan Dogan Leonard, Per Eriksson, Anders A. Bengtssson, Ivo Gunnarsson, Lars Ronnblom, Christopher Sjöwall (Sweden & UK)

P138 Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
Daniel S. Strasser, Estelle Gerossier, Virginie Sippel, Ursula Grieder, Andrea Kieninger-Graeftsch, Gabin Perlot, Hervé Farine, Paulina Kulig, Marcel Keller, Sylvia Praedevaux, Marten Tendelengaun, Mark Murphy, Mariannne Martinic (Switzerland)

P139 SLE overlap with psoriatic arthritis successfully treated with secukinumab
Athena Theodoridou, Despoina Dimopoulou, Alexandros Goryfalias (Greece)

P140 Verdinexor, a Selective Inhibitor of Nuclear Export (SINE), ameliorates cellular and molecular pathogenic immune mechanisms of Systemic Lupus Erythematosus
Javier Rangel-Moreno, Nida Meednu, Neha Nandedkar-Kulkarni, Douglas G. Widman, Jennifer Anolik (USA)

Registries and cohorts

P141 Occurrence of neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus: Results from the Swiss Lupus cohort and meta-analysis of the pertinent literature
Aline Meyer, Lucas M. Bachmann, Urs Steiner (Switzerland)

P142 Lupus Europe – When patients help research
Alain Cornet, Jeanette Andersen, Kirsi Myllyns, Anne Charlet, Annemarie Sluijmers, Helga Ovens (Lupus Europe)

P143 Lupus Europe – What we learned from patient panels
Alain Cornet, Jeanette Andersen, Kirsi Myllyns (Lupus Europe)

P144 Potential reversible causes for fatigue in SLE patients - Differences between mild and severe fatigue
Christina Dusing, Gamal Chehab, Jutta Richter, Oliver Sander, Rebecca Fischer-Betz, Benedikt Ostendorf, Hassan Acar, Ralph Brinks, Matthias Schneider (Germany)

P145 Membranous and proliferative Lupus Nephritis - Analysis of a nationwide multicentre cohort
Filipo Farinha, Sofia Barreira, Maura Couto, Margarida Cunha, Diogo Fonseca, Raquel Freitas, Luis Irves, Mariana Luis, Carla Macieira, Joana Rodrigues, Bernardo Santos, Rita Torres, Ruth Pepper, Anisur Rahman, Maria J. Santos (UK & Portugal)

P146 Fracture risk in Systemic Lupus Erythematosus patients over 25 years
Sara Moreira Pinto, Daniela Garelick, Filipa Farinha, Tatiana Pires, Emon Khan, David Isenberg (Portugal, Israel & UK)
P147 Neurropsychiatric manifestations and mental disorders, a complex spectrum of heterogeneous disease: A descriptive cohort study
Roxana González-Mazario, Jorge Juan Fragio Gil, José Ivorra Cortés, Elena Grau-García, Luis González-Puig, Francisco Miguel Ortiz Sanjuan, Samuel Leal-Rodríguez, Isabel Martínez-Cordellat, Rosa Neguerolés-Albuixech, José Eloy Oller-Rodríguez, Marta De-La-Rubia-Navarro, Inmaculada Chalmeta-Verdejo, Cristina Alcariz-Escandell, Cristóbal Pavez-Peñales, Elviro Vicens-Bernabeu, Carmen Núiéra-Herranz, Inés Cánovas-Olmos, José Andrés Román-Ivorra (Spain)

P148 A study of disease profile of adult and juvenile lupus patients at disease onset at tertiary care centre of Northern India
Neeraj Jain, Lalit Duggal, Sujata Sawhney, Manjiri Agarawal, Jeet Kumar Patel, Mayank Gupta (India)

P149 Association between geographic and climatological conditions and cutaneous manifestations in lupus patients from the Spanish Rheumatology Society Lupus Registry cohort
Raul Menor-Almogro, Alejandro Munoz, Illiga Ruo-Figueroa, Maria Auxiliadora Martin-Martinez, Alejandro Olive, Maria Galinda, Jaime Calvo-Alen, Antonio Fernandez-Nebro, Javier Lopez-Longo, Mariana Andres, Eva Tomero, Esther Uriarte, Mercedes Freire, Javier Norvoie, Jose Maria Pego-Reigosa, on behalf of RELES-SER (Spain)

P150 The evolving clinical presentation of Systemic Lupus Erythematosus in a newly established Caucasian cohort: Low incidence of Lupus Nephritis and high burden of neuropsychiatric disease
Dionysis Nikolopoulos, Myrto Kostopoulou, Antigone Pieta, Theofanis Karageorgas, Aggelos Banos, Dimitris Tseronis, Katerina Havazta, Sofia Flouda, Panagiota Rapsomani, Pelagia Katsimbri, Dimitrios T. Boumpas, Antonis Fanourakis (Greece)

P151 Demyelination with autoimmune features (DAF) – Results from the Attikon cohort
Dionysis Nikolopoulos, Antonis Fanourakis, Dimitris Kritis, Matilda Papathanasiou, Maria Chondrogianni, Panagiota Garatziotis, Antigone Pieta, Triantafyllia Koskas, Konstantinos Voumvourakis, Dimitrios Boumpas (Greece)

P152 Epidemiology and practice patterns in the management of Lupus Nephritis in Australia
Richard Phoon, Fiona Brown, Toby Coates, Sharon Ford, Ashley Irish, Nicole Isbel, Mark Thomas, Kate Wyburn (Australia)

P153 Prevalence, severity and consequences of thrombocytopenia in Systemic Lupus Erythematosus – Single centre cohort analysis
Tatiana Pires, Raquel Coparrós-Ruiz, Pedro Gaspar, David Isenberg (Spain, Portugal & UK)

P154 Antimalarial treatment and minimizing prednisone reduce the risk of infection in SLE patients: A 24-month prospective cohort study
Ana Prata, Mariana Luís, Helena Assunção, Luís Inês (Portugal)

P155 Severe infection prior to diagnosis of Systemic Lupus Erythematosus (SLE) is associated with long-term comorbidities
Yu Deng, Anh Chung, Abel Kho, Yuan Luo, Rosalind Ramsey-Goldman, Theresa Walunas (USA)

P156 Accelerated coronary atherosclerosis – A major cause of myocardial infarction in Systemic Lupus Erythematosus
Isak Samuelsson, Ioannis Parodis, Iva Gunnarsson, Agnete Zickert, Claes Hofman-Bang, Håkan Wallén, Elisabet Svenssong (Sweden)

P157 Update on the real-time collecting system data of SLE Treatment and Research group (CSTAR) registry: Clinical features and remission of patients with Systemic Lupus Erythematosus in China Ziqian Wang, Mengtao Li, Jiuliang Zhao, Qian Wang, Xiaofeng Zeng and CSTAR co-authors (China)

---

Standard of care therapy

P158 Lupus Mastitis: The great mimicker
Rita Cunha, Alice Pimentel, Bernardo Figueiredo Santos, Renata Aguiar, Joana Noronha, Ana Bela Barcelos (Portugal)

P159 Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression in patients is still promoted by dyslipidemia, hypertension, history of Lupus Nephritis and a higher prednisone usage
Sofia Ajeganova, Thomas Gustafsson, Lineia Lindberg, Ingiáld Hofström, Johan Frostegård (Belgium & Sweden)

P160 Risk of CV events and mortality in SLE is associated with accumulated disease-damage, anti-phospholipid syndrome and higher carotid intima-media thickness
Sofia Ajeganova, Ingiáld Hofström, Johan Frostegård (Sweden & Belgium)

P161 Case report of a Systemic Lupus Erythematosus and antiphospholipid syndrome patient with an infiltrative tuberculosis and melanoma: Features of therapeutic approaches
Anastasia Shumilova, Tatiana Reshetnyak, Pariza Chelidze, Maria Cherkasova, Alexander Lila (Russian Federation)

P162 Progression of subclinical cardiovascular disease in SLE: A five year follow up study
Yvati Bakshi, Moura Griffin, Sara Croca, Filipa Farina, David Isenberg, Andrew Nicolaides, Anisur Rahman (UK)

P163 Improving a SLE-Quality Indicator tool in an outpatient tertiary care setting
Jun Chu, Elaine Poncio, Isabel Ochoa, Yenealem Temesgen-Oyelakin, Michael Davis, Sarthak Gupta, Zeran Manna, Marquis Chapman, Eileen Chu, Aiden Donnellan, Saffaraz Hasni (USA)

P164 Value of fatigue: Patients vs. physicians - Time trade-off approach
Christina Dusing, Matthias Schneider, Gamal Chehab (Germany)

P165 Patients with Systemic Lupus Erythematosus and lymphoma at a tertiary hospital
María Galindo, María Martin, Aimara García, Minerva Montalvo (Spain)
P166 Possible new role for HCO in preventing depression in jSLE?
Sara Ganhão, Beatriz Silva, Franciso Aguiar, Mariana Rodrigues, Iva Brito, Margarida Figueiredo-Braga (Portugal)

P167 Long term follow-up of lupus patients under antimalaric treatment: Factors of drop-out
Roxana González-Mazarío, Jorge Juan Frago Gil, José Ivorra Cortés, Elena Grau-García, Luis González-Puig, Francisco Miguel Ortiz-Sanjuán, Samuel Leal-Rodríguez, Isabel Martínez-Cordellat, Rosa Negueroles-Albuixech, José Eloy Oller-Rodríguez, Marta De-la-Rubia-Navarro, Inmaculada Chalmeta-Verdejo, Cristina Alcoliz-Escandell, Cristóbal Pavez-Perales, Elvira Vicens-Bernabeu, Carmen Nójera-Herranz, Inés Cánovas-Olmas, José Andrés Román-Ivorra (Spain)

P168 Prevalence and characteristics of cardiovascular autonomic dysfunction in patients with Systemic Lupus Erythematosus
Amanda Zinglersen, Katrine Iversen, Esben Laugesen, Jesper Fleischer, Søren Jacobsen (Denmark)

P169 Association between cardiovascular autonomic neuropathy and quality of life in patients with Systemic Lupus Erythematosus
Amanda Zinglersen, Henrik Jeffers, Katrine Iversen, Jesper Fleischer, Søren Jacobsen (Denmark)

P170 Antimalarial agent use is associated with favourable physical functioning in patients with Systemic Lupus Erythematosus
Ioannis Parolis, Sofia Soukka, Álvaro Gomez, Yvonne Ennan, Petter Johansson, Sharzad Emamikia, Katerina Chatzidionysiou (Sweden)

P171 Cardiovascular risk in young patients with lupus: Investigating metabolic biomarkers and the immunological phenotype
George Robinson, Kirsty Waddington, Leda Coelewij, Junjie Peng, Anna Radziszewska, Chris Wincup, Hannah Peckham, David Isenberg, Yiannis Ioannou, Ines Pineda-Torra, Coziana Ciurtin, Elizabeth Jury (UK)

P172 Mainzer Lupus Score (MLS) a new questionnaire for lupus treatment
Jessica Hoschek, Matthias Dreher, Simone Boedecker, Julia Weinnmann-Menke, Andreas Schwarting (Germany)

P173 Is use of hydroxychloroquine associated with better patient reported outcomes in lupus?
Meebakshi Jolly, Vinay Sehgal (USA)

P174 Extended arterial ultrasound revealing increased intima media thickness and relation to impaired microcirculation in Systemic Lupus Erythematosus
Christina Svensson, Hanna Jonasson, Tomas Strömberg, Per Eriksson, Christopher Stjøwall, Helene Zachrisson (Sweden)

P175 Despite the high rate of response to treatment, Lupus Nephritis standard of care is still associated with high incidence of chronic kidney disease: A retrospective longitudinal study, from three south- European cohorts of patients in follow-up since 2000
Irene Altadás, José María Pego, Francisco Rubilla, Chiara Stagnaro, Marta Mosca, Íñigo Ruo-Figueroa (Italy & Spain)

P176 A case of Lupus Enteritis successfully treated with anti-TNF alpha inhibitor
Silvia Bilia, Daiana Giannini, Domenico Giannini, Giorria Mumolo, Riccardo Copecochi, Linda Ceccarelli, Paola Migliorini, Antonio Tavoni (Italy)

P177 Work participation in patients with Systemic Lupus Erythematosus: A scoping review
Birgit Blomjous, Gayle Gojadin, Irene Butnik, Alexandre Voskuyl, Louise Falzon, Jan Hoving, Marieke ter Wee (The Netherlands & USA)

P178 Lupus Nephritis was associated with low bone mineral density irrespective of duration on steroid treatment in a large UK study of Juvenile Systemic Lupus Erythematosus
Anastasia-Vasiliki Madenidou, Yasmin Mahmoud, Oliver Chang, Farah El-Sharnouby, Chariene Foley, Coziana Ciurtin (UK)

P179 Systemic Lupus Erythematosus, a pilot study of a new disease activity score
Daphna Poran, Monique Ben-Am, Liran Mendel, Ari Polachek, Victoria Furer, Ofir Elalouf, Jonathan Wallman, Shaye Kivity, Nancy Agmon-Levin (Israel)

P180 Correlation between patient reported outcomes of health-related quality of life and clinical activity in Systemic Lupus Erythematosus patients
Selma Sari, Bahar Artim Esen, Ahmet Göl, Lale Öcal, Murat İnanç (Turkey)

P181 Are quality of life concerns different by sex among patients with Systemic Lupus Erythematosus?
Mamatha Katikaneni, Meenakshi Jolly (USA)

P182 Comparison of SLEDAI-2K and SLEDAI-2KG (glucocorticoid) indexes in patients with Systemic Lupus Erythematosus (SLE)
Nastasia Kifer, Mario Sestan, Emilija Hosticka, Maja Novoselec, Mateja Batrozić Varga, Ivan Padjen, Marijan Fikovic, Domagoj Kifer, Branimir Anic, Drago Batinic, Kristina Potocki, Ivan Malčić, Marija Jelusic (Croatia)
Delay in diagnosis reduces outcome in Systemic Lupus Erythematosus – Cross-sectional analysis of a German long-term study (LuLa cohort)
Anna Kernder, Jutta Richter, Rebecca Fischer-Betz, Borgi Winkler-Rohlfing, Matthias Schneider, Gamal Chehab (Germany)

Predictors of treatment outcome in patients with proliferative Lupus Nephritis: A 36-month retrospective cohort study
Mariana Luís, Rita Prata, Helena Assunção, Luís Inês (Portugal)

Early and sustained responses with anifrolumab in patients with Systemic Lupus Erythematosus (SLE) in 2 phase 3 trials
Eric F. Morand, Richard Furie, Ian Bruce, Kenneth C. Kalunian, Rubiana N. Kalyani, Gabriel Abreu, Lila Pinedo, Raj Tummala (Australia, UK, USA & Sweden)

Systemic Lupus Erythematosus in male - About 5 observations
Benamer Mustapha (Algeria)

Assessment of disease activity and health related quality of life in patients with Systemic Lupus Erythematosus at Kenyatta National Hospital
Eunice Nyambane, Eugene Genga, Loice Achieng, Omondi Oyoo, Fredrick C.F. Otieno (Kenya)

Antiphospholipid antibodies and vascular renal lesions as prognostic factors in Lupus Nephritis
Annamaria Paglionico, Valentina Varriano, Luca Petricca, Clara Di Maria, Maria Rita Gigante, Giacomo Tanti, Barbara Tolussa, Gianfranco Perraccio, Elisa Gremese (Italy)

A simplified approach for patients with SLE to report disease activity using a revised version of the Swedish Systemic Lupus Activity Questionnaire
Susanne Pettersson, Vera Illescas-Bäckelin, Andreas Jönsson, Iva Gunnarsson, Estelle Tysberg, Dag Leonard, Christopher Sjöwall, Elisabet Svenungsson (Sweden)

Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) Registry - Subjective well-being in patients with Systemic Lupus Erythematosus
Yue Shi, Dandan Bi, Y anhong Wang, Ruofan Li, Lijun Wu, Cheng Zhao, Zhenbiao Wu, Xinwang Duan, Jian Xu, Feng Zhan, Min Yang, Shengyun Liu, Qin Li, Shuo Zhang, Lingshan Liu, Jiuliang Zhao, Xinpeng Tian, Xinying Li, Qian Wang, Xiaofeng Zeng, CSTAR Co-authors (China)

USEFUL I: Musculoskeletal ultrasound to identify patients with lupus arthritis with better response to therapy

The registration fee includes
• Participation in all scientific sessions
• Congress bag with the Programme and Abstracts, tourist info and congress related documents
• Access to the exhibition
• Lunches and coffee breaks
• Welcome Reception and Walking Dinner on Wednesday, 25 March
• Guided Tour on Thursday, 26 March

Confirmation
When your registration is completed successfully, you will receive an automatic confirmation. You can also print an invoice when you finalise your online registration.

Payment
All payments are to be made in EURO, net of all bank charges and commission for the receiver. Payment is to be made by:
• Credit Card: Only VISA & MasterCard are accepted
• Bank Wire

Cancellations
Participants cancelling their registration before 15 February 2020, will receive a full refund, less € 50,00 administration costs. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing to the Organising Secretariat. All refunds will be processed after the Meeting.
Social Programme

Welcome Reception and Walking Dinner on Wednesday, 25 March
Registered participants and exhibitors are invited to the Welcome Reception and Walking Dinner in the Foyer of the Concertgebouw.

Participation is included in the registration fee, but pre-registration is mandatory. Partners can register at a price of € 50,00.

Guided Tour on Thursday, 26 March
Official guides will take us on a guided walk through Bruges’ rich history. The walk will end on the centrally located Market Square at 19.30 hrs.

Participation is included in the registration fee, but pre-registration is mandatory. Partners can also register free of charge.

Gala Dinner on Thursday, 26 March
The Gala Dinner will take place at the impressive Belfry, located on the market square. Situated in the very heart of the city, this medieval bell tower with its carillon of 47 melodious bells is the unique setting for a memorable evening.

Separate registration and payment is required (see Registration page for details).

Hotel Accommodation

A number of hotel rooms have been booked at special group rates, including breakfast and VAT.

The list of hotels and rates are available on the website: https://www.lupus2020.eu/hotels/

The listed rates are only valid for reservations made through Medicongress. A hotel room can be booked as part of the registration procedure. Hotel availability cannot be guaranteed after March 1.

Any requests for hotel accommodation must be accompanied by a credit card number in order to secure the room. This credit card will not be charged by the organisers but only serves as a reservation guarantee. Participants will have to pay their hotel room and personal expenses at the reception of the hotel. In case of late cancellation or no show, the room will be charged on the credit card.

A hotel confirmation will be sent by email after receipt of the registration form and housing request and payment of the registration fee.

Each hotel has its proper cancellation policy. For details, please consult the hotel page: https://www.lupus2020.eu/hotels/

The Venue - Concertgebouw

The venue for the Lupus 2020 Meeting will be the Concertgebouw which is located on the ‘Zand’ square in the centre of the city.

The Concertgebouw has its proper underground car park (Parking Het Zand for 500 cars) and is located at a mere 5 minutes’ walk from the railway station where another car park for about 1,500 cars is available.

All hotels are within walking distance and the short walk to the Concertgebouw will give delegates a general impression of Bruges’s architectural and historic splendour.

The Concertgebouw is a cultural centre, completed in 2002 when Bruges was European Capital of Culture. The halls, and the Concert Hall in particular, are famous throughout the world for their perfect acoustics.

Concertgebouw
’t Zand 34
8000 Bruges, Belgium
https://www.concertgebouw.be/en